Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on addressing neuroinflammation through innovative treatments, has announced an inducement grant to a new non-executive employee. The equity award, as per Nasdaq Listing Rule 5635(c)(4), was approved on December 10, 2025, under the 2022 Employment Inducement Award Plan.

The employee has been granted an option to purchase 19,000 shares of Annexon common stock at an exercise price of $4.91, which matches the closing price on the date of grant, December 15, 2025. This option has a ten-year term and includes a vesting schedule where 25% of the shares will become exercisable after one year. Following that initial period, the remaining shares will vest at a rate of 1/48th monthly, contingent on the employee's continued service during the vesting period.

Annexon is at the forefront of developing complement inhibitors aimed at mitigating neuroinflammatory conditions impacting various parts of the body, including the brain and eyes. This approach centers on C1q, which plays a crucial role in the complement pathway associated with inflammation. By targeting C1q, Annexon's therapies aim to proactively inhibit the cascade of neuroinflammation before it can inflict tissue damage prevalent in various diseases.

The company’s therapeutic pipeline spans multiple areas, including autoimmunity, neurodegeneration, and ophthalmology, with the goal of addressing the needs of approximately 10 million individuals across these conditions. Annexon's commitment is to advance breakthrough treatments that significantly enhance the quality of life for patients.

For more information about Annexon and its initiatives, interested parties can visit their website at annexonbio.com.

Annexon, Inc.'s recent inducement grant to a new non-executive employee highlights an important aspect of their strategic recruitment efforts and commitment to long-term value creation. Under Nasdaq Listing Rule 5635(c)(4), this announcement is significant not only in its potential impact on the company’s operational capabilities but also for investors considering the stock's future performance.

The grant, consisting of options to purchase 19,000 shares at an exercise price of $4.91, positions the new employee for a stake in Annexon’s growth trajectory. Given the vesting schedule that spans four years, with a quarter of the shares vesting on the first anniversary, this aligns the interests of the employee with those of the shareholders, promoting long-term commitment and reducing turnover risk.

For investors, the strategic implications of such grants can be twofold. Firstly, it signals that Annexon is bolstering its talent base, which is crucial as the company advances its clinical platform targeting neuroinflammation. The focus on C1q as a novel therapeutic target in complement-mediated diseases presents substantial growth potential, especially in areas with significant unmet medical needs like autoimmunity and neurodegeneration. As the clinical data emerging from these programs matures, the stock could see bullish momentum, and such hires can accelerate development timelines.

Secondly, the option’s exercise price being equal to the recent market closing price indicates the Board's confidence in the stock’s appreciation potential. It is advisable for investors to consider leveraging any market dips as buying opportunities, particularly as developments unfold within their drug pipeline, which serves a patient population of nearly 10 million. Overall, Annexon's commitment to nurturing its talent amid a promising therapeutic landscape presents a compelling case for both current and potential investors.